CAMPERR: cfMeDIP-seq Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse

Principal Investigator

Nima Nabavizadeh

Study Purpose

To train and validate Adela’s cfMeDIP-seq based methylome profiling platform to detect and differentiate multiple cancer subtypes.

Medical Condition(s)

Healthy volunteers, Cancer screening, brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid

Eligibility Criteria

1. ≥40 years of age
2. Able and willing to provide informed consent
3. Should meet one of the following conditions at the time of enrollment:
a) Newly diagnosed (within 90 days) with cancer or a recurrence of a cancer diagnosed >5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian, Pancreatic, Prostate, Renal, Sarcoma, Thyroid, Leukemia, Lymphoma, Multiple Myeloma
b) Not diagnosed with any cancer in the last 5 years (except ductal carcinoma in situ or non-melanoma skin cancer)

Age Range

40 - N/A

Healthy Volunteers Needed


Duration of Participation

This study is expected to take approximately 5 years. This includes approximately 1 year for enrollment, with up to 3 years of follow-up for the controls and up to 4 years of follow-up for the cancer cases

Minors Included




Adela, Inc.

Recruitment End


Compensation Provided



$50 per blood draw

Go Back